Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program (aSAH-Omics) ：A Multicenter Clinical and Mechanistic Study
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening cerebrovascular emergency with high mortality and disability rates. Despite advances in neuroimaging and interventional techniques, outcomes remain poor for many patients due to complex post-rupture complications such as delayed cerebral ischemia (DCI), pneumonia, and other systemic injuries. These secondary events critically affect neurological recovery, yet their molecular mechanisms are not fully understood. This multicenter study aims to investigate the biological basis of post-rupture complications and prognosis in patients with aSAH through integrated multi-omics and clinical data analysis. Biospecimens including blood, cerebrospinal fluid, urine, and other relevant tissues will be collected for genomic, transcriptomic, proteomic, metabolomic, and imaging-omic profiling. By linking molecular data with clinical and imaging indicators, the study seeks to identify key pathways and biomarkers associated with secondary injury and outcome heterogeneity.
• Adult patients aged ≥18 years;
• Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH) by CTA, or DSA;
• Aneurysm secured by either microsurgical clipping or endovascular coiling during hospitalization;
• Time from onset to aneurysm treatment ≤ 72 hours;
• Availability of biospecimens, including blood, cerebrospinal fluid (CSF), urine, or fecal samples collected during hospitalization;
• Signed informed consent obtained from the patient or legal representative.